KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) Debt to Equity (2019 - 2025)

Vir Biotechnology's Debt to Equity history spans 5 years, with the latest figure at $0.02 for Q1 2025.

  • On a quarterly basis, Debt to Equity changed N/A to $0.02 in Q1 2025 year-over-year; TTM through Mar 2025 was $0.02, a N/A change, with the full-year FY2024 number at $0.01, changed N/A from a year prior.
  • Debt to Equity hit $0.02 in Q1 2025 for Vir Biotechnology, up from $0.01 in the prior quarter.
  • Over the last five years, Debt to Equity for VIR hit a ceiling of $0.08 in Q3 2021 and a floor of $0.01 in Q4 2024.
  • Historically, Debt to Equity has averaged $0.04 across 3 years, with a median of $0.04 in 2021.
  • The widest YoY moves for Debt to Equity: up 326.24% in 2021, down 33.24% in 2021.
  • Tracing VIR's Debt to Equity over 3 years: stood at $0.08 in 2021, then crashed by 82.14% to $0.01 in 2024, then rose by 20.09% to $0.02 in 2025.
  • Business Quant data shows Debt to Equity for VIR at $0.02 in Q1 2025, $0.01 in Q4 2024, and $0.08 in Q3 2021.